There is currently huge interest in the development of novel drug formats that could address intracellular protein-to-protein interactions (PPIs) as these targets are beyond the reach of virtually all biological drugs at present.
Cell Penetrating Alphabodies
Complix is focused on developing the next-generation of therapeutics, based on Cell Penetrating Alphabodies (CPABs). There is currently huge interest in the development of novel drug formats that could address intracellular protein-to-protein interactions (PPIs) as these targets cannot be accessed by virtually all biological drugs at present.
Complix´ CPABs have the capability to interact with intracellular disease targets. Their purposefully designed alpha-helical configuration is ideally suited for penetrating cell membranes whilst at the same time remaining stable and biologically active in the intracellular environment.
CPABs are created by integrating specific sequence motifs into the base Alphabody scaffold, allowing them to travel across cell membranes.
Alphabodies without these unique motifs do not penetrate cells and are being developed by Complix to address extracellular disease targets.
CPABs possess a variety of beneficial features that make them highly suited to remain stable and operate effectively in the intracellular environment, including their ability to withstand the action of the many proteases active in the intracellular environment. Moreover, thanks to the unique design of the CPABs’ alpha-helical scaffold they can efficiently interfere with a variety of intracellular PPIs. These include transcription factors and various other key regulatory proteins.